Company intelligence / Profile preview

Sens.ai

Whistler, British Columbia, Canadasens.ai ↗

Ownership: Private
Development stage: Commercial

Overview

Sens.ai has developed a commercial at-home brain training system that combines EEG-based neurofeedback, personalized light stimulation/photobiomodulation, and heart coherence training. The system is designed for cognitive optimization and longevity. It is supported by collaborations with leading research institutes such as the Buck Institute for Research on Aging to study brain aging biomarkers[5]. No clinical trial results in the traditional pharmaceutical sense are reported.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapy (brain training, neurofeedback, photobiomodulation)
Industry: Digital Health Medical Devices

Partnerships

Buck Institute for Research on Aging [5]

Beyond the preview

Go deeper on Sens.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sens.ai.

Explore the full profile